SAN DIEGO and HONG KONG, March 1 /PRNewswire-FirstCall/ -- CellSearch(TM) System, an advanced prognostic platform for the analysis of circulating tumor cells (CTC) in metastatic breast cancer patients, has been successfully launched for commercial application in Hong Kong. The system is provided by Bridgetech Hong Kong Limited, a wholly-owned subsidiary of Bridgetech Holdings International, Inc. “Bridgetech” , a leader in the transfer of Western medical technology to China with an initial focus on oncology.
Bridgetech has installed two sets of the CellSearch(TM) System in Hong Kong, in the University of Hong Kong and the Chinese University of Hong Kong, and the former is now available for use by metastatic breast cancer patients. Taking as little as 7.5 ml of a patient’s blood, the system can perform the capture, identification and classification of CTCs in an automatic, standardized and scientific manner. CTC tracking and analysis provide valuable prognostic information for predicting progression-free survival and overall survival of metastatic breast cancer patients.
Bridgetech invited Dr. Neil Senzer, Scientific Director of Mary Crowley Medical Research Clinics, U.S., a leading oncologist, to visit Hong Kong from February 13 - 15, 2007 to introduce the CellSearch(TM) System to local oncologists. Dr. Senzer lectured at the Tumor Board Meeting at the Hong Kong Sanatorium & Hospital and met the local media with the University of Hong Kong’s Department of Pathology on February 14, 2007. He also seized the opportunity to meet with some breast cancer patient groups on February 15, 2007.
“The new technology has been well received by local oncologists and representatives of breast cancer patient groups and we believe that the commercial application of the CellSearch(TM) System will greatly benefit metastatic breast cancer patients in Hong Kong,” said Carrie Yuen, President, Asia of Bridgetech Holdings International, Inc.
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the U.S. to capitalize on the demand for Western healthcare in Greater China. The company is bringing emerging drugs, devices and diagnostics to Greater China, with an initial focus on oncology. For additional information, please visit www.bthi.com.
Contacts: Media Relations: Vince Heald, Beck Ellman Heald - 858-453-9600 vheald@behmedia.com Investor Relations: Redwood Consultants, LLC - 415-884-0348
Bridgetech Holdings International, Inc.
CONTACT: Media, Vince Heald of Beck Ellman Heald, +1-858-453-9600,vheald@behmedia.com; or Investors, Redwood Consultants, LLC,+1-415-884-0348, both for Bridgetech Holdings International, Inc.
Web site: http://www.bthi.com/
